Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: End Stage Liver Disease
Interventions: Bodystat Quadscan 4000, bodystat quadscan 400; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatic Insufficiency
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Acute Liver Failure, Acute Liver Injury
Interventions: Ornithine Phenylacetate; Drug
Lead sponsor: William Lee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more

Conditions: Cirrhosis, Liver, Liver Diseases
Interventions: Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute-on-Chronic Liver Failure
Interventions: Single Dose G1090N, Multiple dosing of G1090N; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Liver Failure, Liver Neoplasm
Interventions: blood samples; Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy, Hepatic Insufficiency
Interventions: LY3437943; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Chandler, Arizona • DeLand, Florida • Miami, Florida + 1 more

Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions: No interventions; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 8
States / cities: Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more

Conditions: Hepatic Encephalopathy, Cirrhosis
Interventions: Fecal transplant; Biological
Lead sponsor: Jasmohan Bajaj; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions: IDN-6556, Placebo; Drug · Other
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Liver Cancer, Liver Metastases
Interventions: Not listed
Lead sponsor: Maastricht University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • Cleveland, Ohio

Conditions: Hepatitis C, Hepatic Insufficiency
Interventions: HCV-796; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Gainesville, Florida • Orlando, Florida • Saint Paul, Minnesota

Conditions: Hepatic Insufficiency
Interventions: QAB149; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hepatic Insufficiency
Interventions: AG-013736; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy, Hepatic Insufficiency
Interventions: Palbociclib 75 mg Capsule; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Orlando, Florida

Conditions: Critical Illness, Chronic Disease, Terminal Care, Palliative Care, Communication, Advance Care Planning, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, End Stage Liver Disease, Kidney Failure, Chronic
Interventions: Communication Feedback Form for Patients with Serious Illness; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 817 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Renton, Washington • Seattle, Washington

Conditions: End Stage Liver DIsease, Cirrhosis, Liver
Interventions: Fitness intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Interventions: TEST Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Hepatic Encephalopathy
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Cancer, Chronic Obstructive Pulmonary Disease (COPD), Restrictive Lung Disease, Congestive Heart Failure, End Stage Liver Disease
Interventions: Training Program Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 6,086 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Charleston, South Carolina • Seattle, Washington

Conditions: Acute Liver Failure, Intracranial Hypertension
Interventions: Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero; Device
Lead sponsor: Copenhagen University Hospital, Rigshospitalet; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatic Encephalopathy
Interventions: Critical flicker frequency; Diagnostic Test
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: End Stage Liver DIsease
Interventions: Mobilization with G-CSF and Mozobil; Drug
Lead sponsor: Proteonomix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hepatic Insufficiency, Liver Diseases
Interventions: INCB123667; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Chandler, Arizona • Orlando, Florida • San Antonio, Texas

Search by objective public record fields.

End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

Telehealth Intervention in Cirrhotics

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

Mobilization of Mesenchymal Stem Cells During Liver Transplantation

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Fecal Transplant in Recurrent Hepatic Encephalopathy

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Improving Communication About Serious Illness

Use of EL-FIT App to Promote Physical Activity

Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Revealing Engagement Patterns Among Hepatic Encephalopathy Patients

Improving Clinician Communication Skills (ICCS)

Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure

Flicker App for Minimal Hepatic Encephalopathy

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment